Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
Innospec, Inc. (IOSP)
NASDAQMaterialsChemicals - SpecialtySnapshot 2026-11-04
$80.65-18.72%
Close 2026-11-04 · 1-day change
NASDAQMaterialsChemicals - SpecialtySnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
6.15 → 6.17 EPS · FY ending Dec 31, 2027 · 2 analysts
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
Change in the same fiscal period’s mean EPS estimate from Oct 5, 2026 to Nov 4, 2026: (new ÷ prior − 1). Contributor count changed from 2 to 2; this is not the number of analysts revising. The ±10% axis is a display range.
The EPS and P/E reference is not available for IOSP yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Share repurchase program of up to $75 million and semi-annual dividend of $0.92 per share | The company returns capital with $75 million buybacks and $0.92 dividends. | Intact | buyback program or dividend cut or suspension | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Next earnings date unavailable
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
IOSP is an established specialty chemicals business with a mildly favorable, execution-led long-term thesis. Recent results and management progress support the thesis, but the evidence does not establish a high-confidence growth story.
IOSP is valued at a premium to peers, while the expectations gap is somewhat positive and the valuation signals are aligned. The snapshot describes the premium as the main source of fragility, with low overall fragility rather than a broader combination of expensive valuation, weak performance, and turbulence.
Near term, recent financial performance is strong, and management is on track with its stated priorities. Performance Chemicals and Oilfield Services operating income grew year over year, while Fuel Specialties revenue rose and operating income increased modestly. The near-term risk of a miss is described as low, but peer misses and a prior deep miss remain cautions; a guidance cut would be a meaningful negative.
Over the next few quarters, the thesis depends on continued growth and margin improvement in Performance Chemicals and Oilfield Services, alongside steady Fuel Specialties performance. Materials-sector bellwethers such as LIN, ECL, and SHW are useful signals: continued strong results could sustain the sector tailwind, while misses or lower guidance could weaken it.
For the next one to three years, IOSP’s thesis looks intact, supported by recent execution and a favorable sector backdrop, but its peer-premium valuation leaves less room for weak results. The central question is whether management can sustain segment progress without cutting guidance. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| Profit margins stay stable near current levels. |
| Intact |
| profit margin declines more than 200 basis points next year |
Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Revenue grows at least 7% annually | A primary condition in Innospec, Inc.'s published investment case. The stated target is >=7% YoY. | Intact | YoY revenue growth falls below 5% next year | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$6.08 → $6.17 · observed estimates
$1.99B → $2.02B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $6.08 | $1,986,490,980 | 2 / 2 |
| 2026-07-25 | $6.08 | $1,986,500,000 | 3 / 3 |
| 2026-07-26 | $6.08 | $1,986,500,000 | 3 / 3 |
| 2026-07-27 | $6.08 | $1,986,500,000 | 3 / 3 |
| 2026-07-28 | $6.08 | $1,986,490,980 | 2 / 2 |
| 2026-07-29 | $6.08 | $1,986,500,000 | 3 / 3 |
| 2026-07-30 | $6.08 | $1,986,490,980 | 2 / 2 |
| 2026-07-31 | $6.08 | $1,986,490,980 | 2 / 2 |
| 2026-08-01 | $6.08 | $1,986,490,980 | 2 / 2 |
| 2026-08-02 | $6.08 | $1,986,500,000 | 3 / 3 |
| 2026-08-03 | $6.08 | $1,986,500,000 | 3 / 3 |
| 2026-08-04 | $6.08 | $1,986,500,000 | 3 / 3 |
| 2026-08-05 | $6.08 | $1,986,500,000 | 3 / 3 |
| 2026-08-06 | $6.08 | $1,986,500,000 | 3 / 3 |
| 2026-08-07 | $6.15 | $1,995,881,866 | 2 / 2 |
| 2026-08-08 | $6.15 | $1,995,881,866 | 2 / 2 |
| 2026-08-09 | $6.15 | $2,017,066,670 | 3 / 3 |
| 2026-08-10 | $6.15 | $1,995,881,866 | 2 / 2 |
| 2026-08-12 | $6.15 | $1,995,881,866 | 2 / 2 |
| 2026-08-13 | $6.15 | $1,995,881,866 | 2 / 2 |
| 2026-08-14 | $6.15 | $1,995,881,866 | 2 / 2 |
| 2026-08-15 | $6.15 | $1,995,881,866 | 2 / 2 |
| 2026-08-16 | $6.15 | $1,995,881,866 | 2 / 2 |
| 2026-08-17 | $6.15 | $1,995,881,866 | 2 / 2 |
| 2026-08-18 | $6.15 | $1,995,881,866 | 2 / 2 |
| 2026-08-19 | $6.15 | $1,995,881,866 | 2 / 2 |
| 2026-08-20 | $6.15 | $2,017,081,866 | 2 / 2 |
| 2026-08-21 | $6.15 | $2,017,081,866 | 2 / 2 |
| 2026-08-22 | $6.15 | $2,017,081,866 | 2 / 2 |
| 2026-08-23 | $6.15 | $2,017,081,866 | 2 / 2 |
| 2026-08-24 | $6.15 | $2,017,081,866 | 2 / 2 |
| 2026-08-25 | $6.15 | $2,017,081,866 | 2 / 2 |
| 2026-08-26 | $6.15 | $2,017,081,866 | 2 / 2 |
| 2026-08-27 | $6.15 | $2,017,081,866 | 2 / 2 |
| 2026-08-28 | $6.15 | $2,017,081,866 | 2 / 2 |
| 2026-08-29 | $6.15 | $2,017,081,866 | 2 / 2 |
| 2026-08-30 | $6.15 | $2,017,081,866 | 2 / 2 |
| 2026-08-31 | $6.15 | $2,017,081,866 | 2 / 2 |
| 2026-09-01 | $6.15 | $2,017,081,866 | 2 / 2 |
| 2026-09-02 | $6.15 | $2,017,081,866 | 2 / 2 |
| 2026-09-03 | $6.15 | $2,017,081,866 | 2 / 2 |
| 2026-09-04 | $6.15 | $2,017,081,866 | 2 / 2 |
| 2026-09-05 | $6.15 | $2,017,081,866 | 2 / 2 |
| 2026-09-06 | $6.15 | $2,017,081,866 | 2 / 2 |
| 2026-09-07 | $6.15 | $2,017,081,866 | 2 / 2 |
| 2026-09-08 | $6.15 | $2,017,081,866 | 2 / 2 |
| 2026-09-09 | $6.15 | $2,017,081,866 | 2 / 2 |
| 2026-09-10 | $6.15 | $2,017,081,866 | 2 / 2 |
| 2026-09-11 | $6.15 | $2,017,081,866 | 2 / 2 |
| 2026-09-12 | $6.15 | $2,017,081,866 | 2 / 2 |
| 2026-09-13 | $6.15 | $2,017,081,866 | 2 / 2 |
| 2026-09-14 | $6.15 | $2,017,081,866 | 2 / 2 |
| 2026-09-15 | $6.15 | $2,017,081,866 | 2 / 2 |
| 2026-09-16 | $6.15 | $2,017,081,866 | 2 / 2 |
| 2026-09-17 | $6.15 | $2,017,081,866 | 2 / 2 |
| 2026-09-18 | $6.15 | $2,017,081,866 | 2 / 2 |
| 2026-09-19 | $6.15 | $2,017,081,866 | 2 / 2 |
| 2026-09-20 | $6.15 | $2,017,081,866 | 2 / 2 |
| 2026-09-21 | $6.15 | $2,017,081,866 | 2 / 2 |
| 2026-09-22 | $6.15 | $2,017,081,866 | 2 / 2 |
| 2026-09-23 | $6.15 | $2,017,081,866 | 2 / 2 |
| 2026-09-24 | $6.15 | $2,017,081,866 | 2 / 2 |
| 2026-09-25 | $6.15 | $2,017,081,866 | 2 / 2 |
| 2026-09-26 | $6.15 | $2,017,081,866 | 2 / 2 |
| 2026-09-27 | $6.15 | $2,017,081,866 | 2 / 2 |
| 2026-09-28 | $6.15 | $2,017,081,866 | 2 / 2 |
| 2026-09-29 | $6.15 | $2,017,081,866 | 2 / 2 |
| 2026-09-30 | $6.15 | $2,017,081,866 | 2 / 2 |
| 2026-10-01 | $6.15 | $2,017,081,866 | 2 / 2 |
| 2026-10-02 | $6.15 | $2,017,081,866 | 2 / 2 |
| 2026-10-03 | $6.15 | $2,017,081,866 | 2 / 2 |
| 2026-10-04 | $6.15 | $2,017,081,866 | 2 / 2 |
| 2026-10-05 | $6.15 | $2,017,081,866 | 2 / 2 |
| 2026-10-06 | $6.15 | $2,017,081,866 | 2 / 2 |
| 2026-10-07 | $6.15 | $2,017,081,866 | 2 / 2 |
| 2026-10-08 | $6.15 | $2,017,081,866 | 2 / 2 |
| 2026-10-09 | $6.15 | $2,017,081,866 | 2 / 2 |
| 2026-10-10 | $6.15 | $2,017,081,866 | 2 / 2 |
| 2026-10-11 | $6.15 | $2,017,081,866 | 2 / 2 |
| 2026-10-12 | $6.15 | $2,017,081,866 | 2 / 2 |
| 2026-10-13 | $6.15 | $2,017,081,866 | 2 / 2 |
| 2026-10-14 | $6.15 | $2,017,081,866 | 2 / 2 |
| 2026-10-15 | $6.15 | $2,017,081,866 | 2 / 2 |
| 2026-10-16 | $6.17 | $2,015,730,939 | 2 / 2 |
| 2026-10-17 | $6.17 | $2,015,730,939 | 2 / 2 |
| 2026-10-18 | $6.17 | $2,015,730,939 | 2 / 2 |
| 2026-10-19 | $6.17 | $2,015,730,939 | 2 / 2 |
| 2026-10-20 | $6.17 | $2,015,730,939 | 2 / 2 |
| 2026-10-21 | $6.17 | $2,015,730,939 | 2 / 2 |
| 2026-10-22 | $6.17 | $2,015,730,939 | 2 / 2 |
| 2026-10-23 | $6.17 | $2,015,730,939 | 2 / 2 |
| 2026-10-24 | $6.17 | $2,015,730,939 | 2 / 2 |
| 2026-10-25 | $6.17 | $2,015,730,939 | 2 / 2 |
| 2026-10-26 | $6.17 | $2,015,730,939 | 2 / 2 |
| 2026-10-27 | $6.17 | $2,015,730,939 | 2 / 2 |
| 2026-10-28 | $6.17 | $2,015,730,939 | 2 / 2 |
| 2026-10-29 | $6.17 | $2,015,730,939 | 2 / 2 |
| 2026-10-30 | $6.17 | $2,015,730,939 | 2 / 2 |
| 2026-10-31 | $6.17 | $2,015,730,939 | 2 / 2 |
| 2026-11-01 | $6.17 | $2,015,730,939 | 2 / 2 |
| 2026-11-02 | $6.17 | $2,015,730,939 | 2 / 2 |
| 2026-11-03 | $6.17 | $2,015,730,939 | 2 / 2 |
| 2026-11-04 | $6.17 | $2,015,730,939 | 2 / 2 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 3 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.